Medtech startup set to revolutionise cancer diagnostics
Add BT as a preferred source
Singapore
A SINGAPORE-based medtech startup that is looking to bring low-cost, simple-to-use cancer diagnostics tests to the masses, is set to revolutionise the global cancer diagnostics market that is projected to hit some US$168.6 billion in 2020.
VolitionRx has developed a blood-based - therefore non-invasive - test platform that can potentially diagnose a wide range of cancers including colorectal and prostate, two of the most common cancers affecting men and women globally, The Business Times has learnt.
TRENDING NOW
On the board but frozen out: The Taib family feud tearing Sarawak construction giant apart
Not retirement, but a rewiring and fresh perspectives post-DBS, says Piyush Gupta
‘I feel so stupid’: How young Indonesians get stuck on the debt treadmill
Indonesia targets year-end start for US$30 billion clean power exports to Singapore
